Hims-Eli Lilly GLP-1 Deal Meets Summit’s FDA Gamble: Which Biotech ETFs Stand to Gain?

Nvidia Stock—Is the Huang Controversy a Long-Term Risk?

Jensen Probe Please click here for an enlarged chart of NVIDIA Corp (NASDAQ:NVDA). Note the following: This article is about the big picture, not an individual stock. The chart of NVDA stock is being used

Compugen (CGEN) Q3 2026 Earnings Call Transcript

Compugen reported Q3 2026 results with revenue of $3.8 million and net loss of $5.8 million. The company completed enrollment in its MAIA-Ovarian trial for COM701 with data expected by end of Q1 2027. Partnered programs with AstraZeneca (rilvegostomig) and Gilead (GS-0321) continue advancing, with rilvegostomig in 12 Phase III trials. The company introduced UnigenX, expanding its discovery platform into tumor-associated antigens for T-cell engagers. Cash runway extends into 2029 with $117.5 million in cash and equivalents.

Piper Sandler Reiterates Overweight on Moderna, Raises Price Target to $305

Fed's Barkin Says Risk Lies On The Inflation Side Of The Us Central Bank’s Mandate; Direction Of Monetary Policy Is Straightforward, But Best To Move Policy With Care; U.S. Economy Is Remarkably Stable; Resilient Demand Alongside Broad-based Cost Increases Putting Upward Pressure On Prices; Firms Say They Will Be Trying To Pass On Higher Costs; Businesses Are Performing Well, With Remarkable Earnings

'AI safety groups outline their plans for a new Washington' - Semafor Exclusive

'East–West pipeline targeted in Madinah, no injuries or disruption' - Ajel News